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ABSTRACT
Alternative splicing produces functionally distinct
proteins participating in cellular processes includ-
ing differentiation and development. CoAA is a
coactivator that regulates transcription-coupled
splicing and its own pre-mRNA transcript is alter-
natively spliced. We show here that the CoAA gene
is embryonically expressed and alternatively spliced
in multiple tissues to three splice variants, CoAA,
CoAM and CoAR. During retinoic-acid-induced P19
stem cell differentiation, the expression of CoAA
undergoes a rapid switch to its dominant negative
splice variant CoAM in the cavity of the embryoid
body. CoAM functionally inhibits CoAA, and their
switched expression up-regulates differentiation
marker Sox6. Using a CoAA minigene cassette,
we find that the switched alternative splicing of
CoAA and CoAM is regulated by the cis-regulating
sequence upstream of the CoAA basal
promoter. Consistent to this, we show that p54
nrb
and PSF induce CoAM splice variant through
the cis-regulating sequence. We have previously
shown that the CoAA gene is amplified in human
cancers with a recurrent loss of this cis-regulating
sequence. These results together suggest that
the upstream regulatory sequence contributes to
alternative splicing of the CoAA gene during stem
cell differentiation, and its selective loss in human
cancers potentially deregulates CoAA alternative
splicing and alters stem cell differentiation.
INTRODUCTION
Most eukaryotic genes contain interspersed introns that
are removed from pre-mRNA by RNA splicing to yield
functional mRNA (1,2). In addition to constitutive
splicing, the majority of human gene transcripts is
alternatively spliced, producing distinct mRNA products
which contribute greatly to the complexity of the human
proteome (3,4). Alternative splicing is cell-type-speciﬁc
and developmentally regulated (5–7). Splicing variants
yield functionally diﬀerent proteins which are often
critical for speciﬁc cellular functions. In contrast, altered
alternative splicing patterns are often associated with
diﬀerent types of diseases (8), and aberrant alternative
splicing is one of the characteristics of cancer cells (9).
Alternative splicing has been extensively shown to be
coupled with transcriptional regulation. A number of
regulatory proteins may be involved in alternative splicing
decisions. These proteins are in the spliceosome particles,
the SR protein family (10), the heterogeneous nuclear
ribonucleoproteins (hnRNPs) and a number of cofactor
proteins involved in transcriptional regulation (11).
Although intronic and exonic sequence elements within
pre-mRNA are required for splicing, substantial evidence
also suggests that protein complexes recruited by promo-
ter sequences determine, in a transcription-coupled
manner, the choices and patterns of alternative splicing
(12,13). For example, steroid hormones have been shown
to regulate alternative splicing through nuclear hormone
receptors and their coactivators in promoter complexes
(12). One mechanism by which promoter sequences may
inﬂuence splicing is by directing the assembly of splicing
factors on the RNA polymerase II (RNAP) C-terminal
domain during RNA synthesis (14,15).
Coactivator CoAA (coactivator activator) was origin-
ally cloned as a nuclear receptor coactivator TRBP/
NcoA6-interacting protein (16,17). CoAA stimulates
transcriptional activation mediated by nuclear receptors
and transcription factors, and also regulates alternative
splicing through a number of steroid hormone receptor-
stimulated promoters (12,18). CoAA (also known as
paraspeckle protein 2, PSP2) is a major component of
nuclear paraspeckles and is colocalized with splicing
factor p54
nrb (19,20). CoAA is a member of the hnRNP
family and contains two N-terminal RNA recognition
motifs (RRMs) and a C-terminal transcriptional
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glutamine-rich motifs (16,21). Both RRMs and the
C-terminal activation domain are essential for CoAA
activities. The C-terminal repeats are homologous to
sequences in a family of oncoproteins containing EWS
(Ewing’s sarcoma) and TLS/FUS (translocation/fusion in
liposarcoma) (21), which regulate alternative splicing.
The human CoAA gene itself is also alternatively spliced.
One of the splice variants, termed CoAM (coactivator
modulator), contains the N-terminal RRMs but lacks the
C-terminal activation domain (16). CoAM serves as a
natural dominant negative form antagonizing the functions
of CoAA in transcription and alternative splicing (16,18).
We have recently shown that the CoAA gene at
chromosome 11q13 is ampliﬁed in human cancers includ-
ing lung and skin cancers (21). Molecular analysis reveals
the CoAA-coding sequence and its basal promoter are
retained within the amplicon, whereas a upstream
sequence is not (21). The recurring gene aberration with
loss of the CoAA regulatory sequence implies a potential
functional importance of the CoAA gene regulation,
including its alternative splicing. In this study, using an
embryonal carcinoma (EC) P19 stem cell neuronal
diﬀerentiation system, we demonstrate that the expression
of CoAA dramatically switches to its alternative splicing
variant CoAM in cells destined to form the cavity of
embryoid bodies (EBs). Overexpression of CoAM induces
diﬀerentiation marker Sox6 in the absence of retinoic acid
(RA), suggesting the switch from CoAA to CoAM
expression may play an important role in promoting
diﬀerentiation. Furthermore, we show that deletion of a
CoAA upstream regulatory element, which is lost in a
number of cancers, impairs the switch in alternative
splicing from CoAA to CoAM in a CoAA minigene
cassette. In particular, CoAA down-regulation is absent.
Data thus support a model in which loss of the regulatory
element disturbs the balance of alternative splicing of the
CoAA gene and results in constant CoAA expression and
defective CoAM expression. This defect may promote
maintenance of a stem cell phenotype and prevent
diﬀerentiation. In summary, our study indicates that
switched alternative splicing of the CoAA gene is regulated
by its upstream sequence during stem cell diﬀerentiation.
MATERIALS AND METHODS
Immunohistochemistry
Polyclonal anti-CoAA antibody (CoAA speciﬁc, against
307–545 aa) and anti-RRM antibody (against 1–156 aa of
CoAM) were prepared in rabbits by immunization with
GST fusion proteins (Covance). His-tagged CoAA protein
as antigen was crosslinked to the Aﬃ-gel 10 resin
according to the manufacturer’s protocol (Bio-Rad), and
was used for aﬃnity puriﬁcation of anti-CoAA (21).
Sagittal sections of mouse embryonic tissue at E12.5 and
E15.5 were stained with aﬃnity puriﬁed anti-CoAA at a
dilution of 1:250. The P19 EBs were paraﬃn-embedded
and the sections were stained with anti-CoAA, anti-RRM
antibodies at dilution of 1:500 and with anti-active
caspase-3 peptide antibody at 1:200 (USBiological,
C2087-16A). Antibody binding was detected using bioti-
nylated anti-rabbit or anti-mouse IgG F(ab)2 secondary
antibody followed by detecting reagents (DAKO).
Sections were counterstained with hematoxylin.
Immunoblotting
Endogenous CoAA and CoAM in P19 cells were detected
using whole-cell extracts at each diﬀerentiating stage and
probed with anti-RRM antibody. For antibody evalua-
tion, CoAA and CoAM were overexpressed in CV1 cells
under the control of a CMV promoter in pcDNA3 vector
(Invitrogen). Immunoblots were probed with anti-CoAA
and anti-RRM primary antibodies at a dilution of 1:200
and detected with the ECL system (Amersham
Pharmacia).
P19 cell and EScell culture and differentiation
Mouse EC P19 cells were maintained in a-modiﬁed
minimum essential medium supplemented with 7.5%
bovine calf serum and 2.5% fetal bovine serum,
100U/ml penicillin and 0.1mg/ml streptomycin. Cells
were incubated in 5% CO2 at 378C. Undiﬀerentiated
murine EC P19 cells were induced by 500nM all-trans RA
(Sigma) up to 4 days in suspension culture to form EBs
(EB2–EB4). The EBs were trypsinized and plated in tissue
culture dish. The cells were further diﬀerentiated
(D3–D12) for an additional 12 days in the absence of
RA. P19 cells were transfected with the plasmid or siRNA
of CoAA (25nM) (21), when applicable, using
Lipofectamine 2000 reagent (Invitrogen) for 24h before
harvest. Total amounts of DNA for each well were
balanced by adding vector DNA. Mouse embryonic stem
(ES) cells (D3, 129S2/SvPas blastocysts, ATCC) were
maintained on gamma-irradiated (30Gy) mouse embryo-
nic ﬁbroblast feeder layers. The culture and diﬀerentiating
conditions were as previously described (22). Brieﬂy,
neuronal diﬀerentiation of ES-cell-derived EBs was
induced by 1000nM RA for 6 days to form EBs (EB2–
EB6). Undisrupted EBs were diﬀerentiated in culture in
the absence of RA for an additional 15 days (D3–D15)
before harvest.
Luciferase assay
CV-1 cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium, supplemented with 10% fetal bovine serum
and 100U/ml penicillin and 0.1mg/ml streptomycin, and
were incubated in 5% CO2 at 378C. CV-1 or P19 cells
were transfected in triplicate in 24-well plates using
Lipofectamine 2000 (Invitrogen). Cells were incubated
with ligand dexamethasone (100nM) to induce MMTV-
luciferase reporter, when applicable, for 16h before
harvest. Total amounts of DNA for each well were
balanced by adding vector DNA. Relative luciferase
activities were measured by a Dynex luminometer. Data
are shown as means of triplicate transfections standard
errors.
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To facilitate promoter analysis, a shortened CoAA minigene
was constructed as shown in Figure 5A. The CoAA
minigene was designed to prevent the expression
of functional CoAA and CoAM proteins that otherwise
might interfere with splicing of its own minigene.
Excluding the promoter region, the human CoAA gene
spans  11kb containing three exons, nt 1–432, 7589–9053
and 9836–10718 (Figure 5A). Deletions were introduced
to the minigene within the ﬁrst intron (645–7419), within
the second exon (7876–8801) that encodes the activation
domain, and within the third exon (10044–10718)
containing the 30 untranslated region. A 1-nt (G) insertion
in the ﬁrst exon disrupted the open reading frame and
prevented the production of RRM domains. Expression
of CoAA and CoAM transcripts was detected using vector-
speciﬁc primers that distinguish the minigene and the
endogenous gene transcripts. A cassette consisting of the
CoAA minigene linked naturally to various fragments of its
own promoter was inserted into a promoter-less pcDNA3
vector (BglII to XhoI). As a control, a separate construct
was prepared with the CoAA minigene expressed under the
control of a CMV promoter in pcDNA3.
RT-PCR and real-time quantitative PCR
Normalized ﬁrst-strand cDNAs from multiple normal
human tissues and cancer cell lines (MTC
TM panels,
Clontech) were analyzed by PCR using primer pairs
common to all CoAA splicing forms. For P19 cells, total
RNA was isolated at each diﬀerentiation stage using
Trizol reagent (Invitrogen), treated with DNase I, and
normalized for their concentrations before use. RT-PCR
was performed using the one-step RT-PCR kit (Qiagen).
In transfection experiments, P19 cells were cotransfected
with CoAA minigenes and p54
nrb or PSF expression
plasmids. Primer pairs used in RT-PCR are as follows:
(from 50 to 30) primers common to endogenous CoAA,
CoAM and CoAR splicing forms, atgaagatattcgtgggcaa,
ctaaacgccggtcggaacc; CoAM-speciﬁc, tctccaccaagggtatg
gtt, ctacatgcggcgctggta; Nanog, agggtctgctactgagatgctctg,
caaccactggtttttctgccaccg; Oct4, ctgagggccaggcaggagcac
gag, ctgtagggagggcttcgggcactt; Sox6, cagcggatggagagg
aagcaatg, ctttttctgttcatcatgggctgc; MAP2, ggacatcagcct
cactcacaga, gcagcatgttcaaagtcttcacc; GFAP, gaatgactcctc
cactccctgc, cgctgtgaggtctggcttggc; and GAPDH, accaca
gtccatgccatcac, tccaccaccctgttgctgta. Primer pairs for
detecting transcripts from the CoAA minigene are as
follows: F, aatgtgtcggctgcatgc; B, ctaaacgccggtcggaacc;
C, tatgaagagatacgccctggttcc; V, atggctggcaactagaaggcac;
J, tctccaccaagggtatggtt; and A, gcctggctggccgcggtag.
Real-time quantitative RT-PCR primers: CoAA, cttcgac
taccagcaggctttt, ccgtcagaggcgccacataag; and CoAM, caaa
gaagtgaagggcaagc, aatccagcgaggactttgtc. Quantitative
RT-PCR was performed on iCycler (BioRad) using
SYBR Green I (Invitrogen).
Chromatin immunoprecipitation (ChIP)
P19 cells at each stage of diﬀerentiation were treated with
1% formaldehyde for 10min, and the crosslinking was
stopped by 125mM glycine. Cells were lysed and
sonicated in the buﬀer containing 20mM Tris pH 8.0,
75mM NaCl, 75mM KCl, 1mM EDTA, 1mM EGTA,
1% Triton X-100, 10% glycerol, 1mM DTT and protease
inhibitors. Immunoprecipitation was carried out using
salmon sperm DNA-blocked protein A/G resin (Upstate),
and anti-RNAP II (8WG16, Covance), or anti-SRp20
(Santa Cruz), or anti-NF-YA (Santa Cruz), or anti-p54
nrb
(BD biosciences) in the above buﬀer except with 0.1%
Triton at 48C overnight. The resin in the absence of
antibody was a control. The crosslinking was reversed
by eluting with 0.1M NaHCO3, 1% SDS, 0.3M
NaCl at 658C for 4h. Puriﬁed DNA (Qiagen kit) was
subjected to PCR analysis. Input was 1% extract
before immunoprecipitation. Primer pairs used are the
following:  80bp, ggccggaggtagctcttctgac, ctccacaggaatgg
ctggcgac;  3000bp, attagaaatgcctttcaagggg, cttcggctgata
gtggacatac; and  8500bp, caggcggactcggttctttgag,
caaacctcatatacggagtcgc.
Sequenceanalyses andCoAR accession
Alu repeats within the regulatory sequences of the CoAA
gene were identiﬁed using Censor Server at Genetic
Information Research Institute (www.girinst.org) and
the BLAST search at the National Center for
Biotechnology Information (NCBI). Transcription-
factor-binding sites within the CoAA basal promoter
were predicted by the TFSEARCH program at the
Computational Biology Research Center of Japan
(www.cbrc.jp). Human CoAR sequences reported in this
article have been deposited at GenBank/EBI Data Bank
with accession number DQ294957.
RESULTS
Alternative splicing ofCoAA gene transcripts
The human CoAA gene (gene symbol RBM14) contains
three exons spanning  11kb. We have previously shown
that the CoAA gene is alternatively spliced and produces
CoAA and CoAM transcripts through competitive 50
alternative splicing events between the second and third
exons (Figure 1A) (16,21). The resulting CoAA and
CoAM proteins share two N-terminal RRM domains, but
only CoAA possesses the C-terminal activation domain
containing repeated YxxQ motifs (16, 21). Consequently,
CoAA is a potent transcriptional coactivator, whereas
CoAM competes with CoAA via shared RRM domains
and represses CoAA activities in both transcription and
splicing (16,18). In this study, using RT-PCR analysis we
identiﬁed a third splice variant of CoAA, designated here
as CoAR (coactivator regulator), in multiple human adult
and embryonic tissues, and in cancer cell lines (Figure 1B).
Sequencing analysis indicated that the CoAR transcript
was derived by joining the ﬁrst and third exons, skipping
the entire second exon and altering the reading frame
for the third exon. CoAR contains only one RRM domain
encoded by the ﬁrst exon. The transcriptional activity
of CoAR is moderately repressive when expressed in
a transient transfection assay (Figure 1C). This splice
variant was previously undetected due to its low
Nucleic Acids Research, 2007, Vol. 35, No. 6 1921abundance in HeLa cells (Figure 1B), in which CoAA and
CoAM were originally cloned. The nucleotide and amino-
acid sequences of CoAR have been deposited at the NCBI
with accession number DQ294957.
The CoAA mRNA transcript is expressed in all
tissues and cells examined as shown by RT-PCR
(Figure 1B), a result consistent with previous northern
blot analysis (16). Sequence analyses conﬁrmed
that the three PCR products observed are the three
CoAA splice variants. The CoAA transcript is relatively
abundant in both normal tissues and cancer cell
lines (Figure 1B). However, the relative levels of CoAA,
CoAM and CoAR mRNAs vary between samples. In some
human fetal tissues and cancer cell lines, CoAM or CoAR
expression is below the limits of detection. The variation in
the expression ratios of CoAA isoforms, which could
partially due to the alternative splicing regulations,
represents a possible cell-speciﬁc control of CoAA activity
through its inhibitory splice variants.
Switched alternative splicing ofCoAA and CoAMduring
P19 stem cell differentiation
To investigate CoAA alternative splicing in a physiological
context, we analyzed a murine EC stem cell line, P19, during
neuronal diﬀerentiation. P19 is a teratocarcinoma-derived
pluripotent stem cell line that can give rise to all three
germ layers in mice (23). Undiﬀerentiated P19 EC cells in
culture can be induced by RA to diﬀerentiate to neuronal
and glial cells (24,25) or by DMSO to cardiac and skeletal
muscles (26). Treatment of P19 EC cells with RA for up to
4 days induces non-adhering aggregates called EBs which
resemble the inner cell mass of embryos (27,28). Prolonged
culture in the absence of RA for an additional 12 days
induces neuronal diﬀerentiation into a mixture of cell
types including diﬀerentiated neurons and glial cells, as
well as a variety of partially diﬀerentiated or undiﬀer-
entiated cells (23).
We analyzed the expression of endogenous CoAA and
its splicing variant transcripts using RNA isolated at
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Figure 1. Alternative splicing of the CoAA gene. (A) Schematic representation of the CoAA gene structure. Introns are shown as lines and the three
exons as numbered boxes with alternative splicing events depicted. The spliced mRNAs and their respective protein structures are shown at right.
(B) RT-PCR analysis of endogenous CoAA, CoAM and CoAR in human adult and fetal tissues as well as cancer cell lines using GAPDH as
a control. (C) Transcriptional activities of CoAA splicing variants were analyzed in CV-1 cells using MMTV-luciferase reporter system, in the
presence or absence of dexamethasone (Dex). CoAA activates, and CoAM and CoAR repress the transcriptional activity.
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Expression of CoAA shows a rapid but transient decrease,
reaching the minimum at Day 4 corresponding to the
EB formation (Figure 2A). In contrast, the expression of
CoAM is drastically increased during EB formation,
reaching the maximum level at Day 4 and declining
rapidly during further diﬀerentiation. These data indicate
that an alternative splicing switch between CoAA and
CoAM occurs during EB formation. The expression of
CoAR is very low and without signiﬁcant change at the
EB stage (Figure 2A). We focused our subsequent analysis
on CoAA and CoAM. The switched expression was
conﬁrmed using primer pairs common to both CoAA and
CoAM (Figure 2B), and was quantitatively measured
by real-time PCR analysis (Figure 2C). A number of
diﬀerentiation markers were analyzed simultaneously as
controls. The expression of Nanog (29) followed by Oct4
(30,31), and then by CoAA declines upon RA treatment
(Figure 2A). Meanwhile, the expression levels of Sox6,
a member of the Sox (SRY box) gene family (32–34),
microtubule-associated protein-2 (MAP2), a neuronal
marker, and glial ﬁbrillary acidic protein (GFAP), a glial
cell marker, increase sequentially during neuronal diﬀer-
entiation. These data together suggest that a switched
expression of CoAA transcripts occurs during the EB
stages of P19 cell diﬀerentiation. We also examined mouse
ES cells and switch from CoAA to CoAM expression was
also found in ES cells during EB formation (Figure 2D).
Figure 2. Alternative splicing switch from CoAA to CoAM during P19 embryonal carcinoma cell diﬀerentiation. (A) Undiﬀerentiated P19 cells (EC)
were induced with 500nM retinoic acid (RA) in suspension culture up to 4 days to form embryoid bodies (EB2–EB4) which were trypsinized and
further diﬀerentiated in the tissue culture dish for an additional 12 days in the absence of RA (D3–D12). Total RNA was isolated and normalized
at each stage and analyzed using gene-speciﬁc primers as indicated by RT-PCR. GAPDH was the control. (B) CoAA and CoAM were analyzed by
RT-PCR using shared primers. (C) The relative quantity of CoAA and CoAM was analyzed by quantitative real-time PCR. (D) Mouse ES cells were
induced with 1mM RA for 6 days. The EB was undisrupted in continuous culture for 15 days in the absence of RA. RT-PCR was carried out using
RNA isolated at each stage.
Nucleic Acids Research, 2007, Vol. 35, No. 6 1923Since the EB of ES cells was undisrupted in continued
culture condition, the down-regulation of CoAM was
delayed, correlating to the presence of EB. In addition to
RA-induced neuronal diﬀerentiation, the switched expres-
sion of CoAA and CoAM was also detected during
DMSO-induced muscle diﬀerentiation of P19 cells (not
shown). These results indicate that the increase of CoAM,
which inhibits CoAA transcriptional activity, might be
common in diﬀerent type of stem cell diﬀerentiation at the
EB stage.
To detect the expression of CoAA and CoAM at the
protein level, we evaluated the two CoAA polyclonal
antibodies. One was raised against the two N-terminal
RRM domains (anti-RRM) for detecting both CoAA
and CoAM, and the other was raised against the
CoAA-speciﬁc C-terminal activation domain (anti-
CoAA). A CoAM-speciﬁc antibody is not feasible due
to its overlapping primary sequence with CoAA. The two
antibodies detected both endogenous and overexpressed
CoAA in 293 cells (Figure 3A). The endogenous CoAM
protein level is very low in this cell line, which is consistent
with its mRNA level (Figure 1B).
Since CoAM mRNA is signiﬁcantly elevated in EBs of
P19 cells, we compared the staining pattern of the two
antibodies to infer the expression pattern of CoAM. EBs
are large multi-cell aggregates that form cavities at Day 4
of RA induction (Figure 3B) (25,27). CoAA expression,
assessed by anti-CoAA, was detected in almost all cells of
early-stage EBs, but only in the outer layer of mature EBs.
CoAA was not detected in the EB cavity (Figure 3C).
In contrast, the high level of expression of CoAM,
detected by anti-RRM with the comparison of anti-
CoAA, was found predominantly within the EB cavity
(Figure 3C). The majority of signals within the cavity is
unlikely contributed by CoAR when the mRNA level is
considered, especially, when further conﬁrmed by western
blot analysis (Figure 3D). Most of the CoAM protein
appears to be in cytoplasm although a low level of nuclear
CoAM may also be present (Figure 3C). This pattern was
also conﬁrmed by overexpression of a Flag-tagged CoAM
in P19 cells (Supplementary Figure S3). A mechanism in
regulating the nuclear–cytoplasm shuttle of CoAM at this
stage is unclear, however, other splicing regulators have
been reported to be shuttled between the nucleus and the
cytoplasm (35). The rapid decline of CoAM expression in
later stages of diﬀerentiation might be due to the loss of
CoAM-containing cells through apoptosis in the cavity,
where a high level of cleaved active caspase-3 was present
(Figure 3C). CoAM mRNA levels appear to decline more
rapidly than CoAM protein levels (Figures 2A and 3D).
At the D3 stage, CoAM protein still remains but CoAM
mRNA is almost absent. This is possibly due to the longer
protein half-life and the shorter mRNA half-life during
degradation processes when cells become apoptotic.
Our data together suggest that cells expressing CoAM
are located in the EB cavity. Since CoAM potently
represses transcription (16), it may regulate target gene
expression and splicing during essential steps of cavitation
at the EB stage.
To conﬁrm the involvement of CoAA in neuronal
diﬀerentiation, we compared the endogenous CoAA
protein expression patterns in mouse embryonic tissues
at gestational stages of E12.5 and E15.5 by immunohisto-
chemistry. In the developing brain, CoAA is widely
expressed in the neocortex at E12.5. The expression is
reduced in the ventricular zone at E15.5, but is enriched in
neurons migrated to the cortical plate that raises cerebral
cortex (Figure 3E). Due to the high expression level of
CoAA and low expression levels of CoAM and CoAR,
the anti-RRM antibody that detects all three CoAA
splicing forms was unable to distinguish from anti-CoAA
in immunohistochemical staining (data not shown).
However, the data did not exclude the possibility
that CoAM and CoAR are present in certain
tissues, in which their mRNAs were detected by PCR
(Figure 1B). In addition, high levels of CoAA expression
were detected in almost all fetal tissues at E12.5
(Supplementary Figure S1). By contrast, at E15.5,
CoAA expression appeared to be restricted to certain
cell types during diﬀerentiation (Supplementary Figure
S2). These results nonetheless suggest that the CoAA is a
predominant form and is expressed in a cell-speciﬁc
manner during diﬀerentiation in multiple tissues including
brain.
Decreased CoAA and increased CoAM induce Sox6
expression in P19 cells
The ability of CoAM to antagonize CoAA function,
together with the dramatic decrease of CoAA and the
increase of CoAM in the EB cavity, raise the possibility
that the switch of CoAA and CoAM might be involved
in regulating diﬀerentiation. To test this hypothesis, we
altered CoAA and CoAM levels by overexpressing or
RNAi, and monitored the expression level of diﬀerentia-
tion marker genes, including Sox6 and MAP2. Sox6 is
a member of a protein family deﬁned by a high mobility
group protein domain, called SRY box. Sox family
proteins are widely involved in diﬀerentiation including
sex determination, and in brain, bone and muscle
development (36). Sox6 is known to be up-regulated
during neuronal diﬀerentiation in P19 cells (32) and
has a function in pre-mRNA splicing (37). Since the
up-regulation of CoAM is immediately followed by that of
Sox6 (Figure 2A), we chose Sox6 as one of the marker
genes for analysis. We overexpressed CoAM or applied
CoAA RNAi in undiﬀerentiated P19 cells in the absence
of RA. The siRNA for CoAA was evaluated in P19 cells
(Supplementary Figure S4) and was previously described
(21). While earlier diﬀerentiation markers such as Nanog
or Oct4 did not change levels in the absence of RA
induction, the expression of Sox6 and the neuronal marker
MAP2 was induced by overexpressing CoAM or by the
treatment with CoAA siRNA in the absence of RA
(Figure 4). The endogenous CoAA level was decreased
during both treatments. The data indicate that CoAA and
CoAM may be speciﬁc in regulating a subset of genes
including Sox6, especially in their downstream diﬀerentia-
tion pathways. However, the increased Sox6 level was
transient in contrast to the eﬀect of RA induced
diﬀerentiation, which produced a sustained elevation of
Sox6. The relapse eﬀect might be due to the transient
1924 Nucleic Acids Research, 2007, Vol. 35, No. 6AB D
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Figure 3. Expression of CoAA in embryoid body of P19 cells and in brain of mouse embryo. (A) Evaluation of anti-RRM and anti-CoAA antibodies
using western blot analysis by overexpression of CoAA and CoAM in 293 cells. (B) Light microscopy of P19 cells at indicated diﬀerentiation stages
( 400). (C) Embryoid body at Day 4 was paraﬃn-embedded, sectioned and stained with anti-RRM (against both CoAA and CoAM), anti-CoAA
(against CoAA only) and anti-active caspase-3 (against cleaved caspase-3) antibodies. Two representative views are shown ( 400). Enlarged views are
shown below. The results show CoAM and active caspase-3 staining in the EB cavity. (D) Western blot analysis of CoAA, CoAM and CoAR at
indicated diﬀerentiation stages of P19 cells. (E) Immunohistochemistry analyses of mouse embryonic brain at gestation stages of E12.5 and E15.5.
The sagittal sections were stained with aﬃnity-puriﬁed anti-CoAA antibody (1:200) and counterstained with hematoxylin ( 400).
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(Figure 4). These data nevertheless suggest that CoAA
and CoAM are able to directly or indirectly regulate Sox6.
It is still yet to be known whether CoAA and CoAM are
necessary or suﬃcient to maintain the diﬀerentiation
program in the absence of RA induction. In summary,
the ratio of CoAA and its dominant negative CoAM may
be critical during P19 stem cell diﬀerentiation, particularly
at the EB stage.
Construction of CoAA minigene
Alternative splicing is regulated at multiple levels,
particularly when coupled with transcriptional activation
(11,14). Evidence has suggested that alternative splicing
can be regulated through intronic or exonic enhancers
and silencers as well as diﬀerential usage of promoter
and regulatory sequences (10,13). We have previously
identiﬁed the loss of cis-regulatory sequences of ampliﬁed
CoAA gene in human cancers (21), suggesting that this
sequence may play an important regulatory role. To
investigate if this sequence regulates the alternative
splicing of the CoAA gene in P19 cells, we constructed a
shortened CoAA minigene with intact splicing junctions.
The minigene is under the control of CoAA promoter with
or without its native cis-regulating sequences. Thus, the
CoAA minigene splicing can be analyzed in P19 cells using
transient transfection approach.
The design of the minigene ensures that no functional
CoAA or CoAM protein is expressed but alternative
splicing capability is preserved. The rationale for this
design is to eliminate the potential eﬀect of the CoAA
protein in regulating its own splicing. The CoAA minigene
was constructed with a shortened ﬁrst large intron,
a reading frame-shift mutation in the ﬁrst exon and a
deletion within the second exon encoding the activation
domain (Figure 5A) (see Materials and methods section).
A minimum of 160 nucleotides surrounding each splicing
site was left intact. The minigene was ﬁrst evaluated under
a CMV promoter by RT-PCR using vector-speciﬁc
primers to avoid endogenous interference (Figure 5A
and B). The results demonstrate that the CoAA minigene
was capable of producing both CoAA and CoAM
equivalent transcripts, when CoAA and CoAM cDNAs
were used as positive controls (Figure 5B). We also
veriﬁed that the CoAA minigene has no coactivator eﬀect
on activation of an MMTV-luciferase reporter, which is
consistent with the predicted absence of CoAA or CoAM
functions (Figure 5C). Although potential intronic or
exonic regulatory elements in the minigene could be
aﬀected, our data indicate that the CoAA minigene
preserves its splicing capability (Figure 5B), as well as its
switching capacity (see below).
The minigene was then constructed under control
of the CoAA basal promoter with various lengths of its
upstream cis-regulatory sequence to evaluate the regula-
tion of the alternative splicing switch in P19 cells. The
human CoAA gene contains a highly GC-rich basal
promoter with predicted transcription-factor-binding
sites for Sp1 and NF-Y (Figure 5D and Supplementary
Figure S5). These transcription-factor-binding sites and
CoAA siRNA CoAM
overexpression
Untreated Retinoic acid
Induction
EC EB2 EB4 D3 EC EB2 EB4 D3 EC EB2 EB4 D3 EC EB2 EB4 D3
MAP2
GAPDH
Sox6
Nanog
CoAA
CoAM
Oct4
Figure 4. Overexpression of CoAM and treatment with CoAA siRNA induce Sox6 expression in the absence of retinoic acid. P19 cells were
transfected with CoAM or with CoAA-speciﬁc siRNA (25nM) at the EC stage, and then were cultured in suspension for 4 days in the absence of
RA induction. The cells were trypsinized, plated and further cultured for 3 days. The untreated and RA-induced (for 4 days) P19 cells were similarly
cultured as controls. RT-PCR analyses were carried out with indicated marker genes at each indicated stage.
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and rat species. Within a 10kb sequence upstream of the
human CoAA gene, there are 21 Alu repeats, which belong
to the short interspersed repetitive sequences (SINEs)
(Figure 5D). A similar pattern of SINEs is also present in
the mouse CoAA gene. We have previously cloned 5kb of
the human CoAA upstream sequence and generated a
series of deletion fragment constructs with a luciferase
reporter (Figure 5D and E) (21). Serial deletions of this
Alu-rich sequence signiﬁcantly increased the reporter
expression in P19 cells, suggesting that this region contains
a cis-acting silencing element in transcription (Figure 5E).
Further deletion of the basal promoter region successively
reduced the transcription activity, indicating that an
intact basal promoter is essential for gene activation.
Together, these data suggest that an Alu-containing
Figure 5. Construction of CoAA minigene. (A) Diagrams show structure of the native CoAA gene and minigene constructions (not to scale). Three
CoAA exons are shown as numbered boxes with their alternative splicing events indicated. In the CoAA minigene, the ﬁrst intron, the second exon
(2b) coding the activation domain and 30 untranslated region within the third exon were shortened. A frame-shift mutation was introduced into the
ﬁrst exon to prevent production of RRM domains. The minigene was linked to a CMV promoter or to its natural 50 sequences (not shown).
(B) CMV-minigene was transfected and its CoAA and CoAM equivalent transcripts were analyzed by RT-PCR using overexpression of their cDNAs
as controls. Vector-speciﬁc and isoform-speciﬁc primers are indicated in (A). (C) The CoAA minigene shows the absence of transcriptional activity in
a luciferase reporter assay using CoAA and CoAM as controls. (D) Diagram illustrates the CoAA ﬁrst exon and its upstream regulatory sequences.
Orientated arrows depict Alu repeats, Alu-Y in black; Alu-S in gray; and Alu-J in white. Enlarged basal promoter region shows predicted Sp1 and
NF-Y binding sites as black or white squares, respectively (Supplementary Figure S5). Numbers indicate the length of promoter fragments analyzed.
(E) The CoAA promoter fragments, indicated in (D), were linked to luciferase reporter and analyzed by transient transfection assays in P19 cells.
Nucleic Acids Research, 2007, Vol. 35, No. 6 1927cis-regulating element and the CoAA basal promoter
are functionally required in P19 cells. The various
lengths of the cis-regulating sequences in the CoAA
minigene were then compared in subsequent splicing
analysis.
p54
nrb andPSF are involvedin regulating of
the alternative splicing of CoAM
We ﬁrst tested the alternative splicing of the CoAA
minigene in P19 cells using two well-characterized splicing
regulators, polypyrimidine tract binding protein-
associated splicing factor (PSF) and p54 nuclear
RNA-binding protein (p54
nrb). PSF and p54
nrb are
RRM-containing proteins that have been suggested to
regulate pre-mRNA splicing and to associate with
transcription and splicing complexes (38–43). Both endo-
genous PSF and p54
nrb are present in undiﬀerentiated
P19 cells (not shown). In the absence of RA induction,
overexpression of either PSF or p54
nrb in undiﬀerentiated
P19 EC cells induced a very signiﬁcant elevation of
endogenous CoAM, but not of CoAA (Figure 6A). The
stimulation of CoAM expression by PSF and p54
nrb was
also evident in cells transfected with the P0 minigene,
that carries the cis-regulating Alu-containing sequence
( 5000 to þ88) (Figure 6A). However, there was much
less induction of CoAM transcript when the CoAA P2
minigene was driven only by the CoAA basal promoter
( 1320 to þ88) under the same condition. In addition,
p54
nrb, but not PSF, signiﬁcantly induced CoAM expres-
sion from the CoAA minigene driven by a CMV
promoter. These data suggest that inclusion of the cis-
regulating sequence in the minigene promotes CoAM
splicing similar to that in the endogenous gene. In
contrast, CMV has a diﬀerent promoter protein complex
assembly, which may permit regulation by p54
nrb but not
by PSF. The p54
nrb mRNA is relatively constant while
PSF mRNA increased in RA-induced P19 cells as detected
by RT-PCR analysis (not shown). There is no apparent
correlation between the expression levels of p54
nrb and
PSF and the switch from CoAA to CoAM during
RA-induced diﬀerentiation. Thus, the involvement of
p54
nrb and PSF in regulating alternative splicing of the
CoAA gene might be due to their protein modiﬁcations
at the particular diﬀerentiation stage. RA may induce
certain signaling pathways that lead to the p54
nrb/PSF
activation in a splicing complex responsible for CoAM
expression. Our data minimally suggest that the alter-
native splicing of CoAM can be regulated through PSF
and p54
nrb, although other splicing factors might also be
involved. The data also indicate that the promoter
and upstream cis-regulating sequences are involved in
alternative splicing decisions.
To seek potential mechanism for the involvement of
CoAA promoter and regulatory sequence in alternative
splicing, we performed chromatin immunoprecipitation
(ChIP) analysis using antibodies against p54
nrb, RNAP II,
one of the SR proteins named SRp20, and transcription
Figure 6. PSF and p54
nrb regulate alternative splicing of the CoAA gene through the cis-regulating sequences. (A) Undiﬀerentiated P19 cells were
transfected with CoAA P0- or P2-minigene, or CMV minigene together with splicing factors p54
nrb or PSF. The expression of CoAA and CoAM
equivalent transcripts was analyzed by RT-PCR. GAPDH was a control. (B) Chromatin immunoprecipitation (ChIP) analysis of CoAA basal
promoter region ( 80bp) and upstream cis-regulating sequences ( 3000 and  8500bp) using anti-NF-Y, anti-p54
nrb anti-RNAP II and anti-SRp20
during P19 cell diﬀerentiation. Input was 1%. The resin in the absence of antibody was a control. (C) The ﬁgure depicts the interactions (dashed
arrows) between cis-regulating sequences and potential splicing and promoter complexes containing RNAP II, p54
nrb, SRp20 and NF-Y. Paired
arrows indicate the primer locations.
1928 Nucleic Acids Research, 2007, Vol. 35, No. 6factor NF-Y, whose binding sites are present in the CoAA
promoter (Supplementary Figure S5). ChIP analysis sug-
gests that there are physical interactions of protein
complexes containing p54
nrb, RNAP II, SRp20 and NF-Y
with the CoAA basal promoter region as well as the
Alu-containing cis-regulating sequences (Figures 6B and C).
NF-Y, RNAP II, p54
nrb and SRp20 all strongly interact
with the CoAA basal promoter region ( 80bp) at all time
points of RA induction. However, they have varied
interaction strength with the cis-regulating sequences
( 3000 and  8500bp) during diﬀerentiation. In particu-
lar, their interactions are generally increased at the EB2
stage. p54
nrb, however, has a diﬀerent interacting pattern,
in which the interaction with the  3000-bp region is more
constant than the interaction with the  8500-bp region
(Figure 6B). The alteration of interaction level during RA-
induced diﬀerentiation is correlated with the early stage of
EB formation. Although the details of the interacting
pattern during diﬀerentiation may be complex, our data
suggest that there are interactions among promoter/
enhancer complexes and splicing factors including
p54
nrb. These data further support that alternative splicing
regulation may require the cis-regulating sequence and the
basal promoter of the CoAA gene.
The cis-regulating sequence isresponsible foralternative
splicing switch from CoAA toCoAM during P19 cell
differentiation
To examine the upstream cis-regulating sequence in
regulating alternative splicing of CoAA and CoAM
during P19 cell diﬀerentiation, we compared the CoAA
minigene with diﬀerent lengths of the cis-regulating
sequence. During RA-induced EB formation, the endo-
genous CoAA gene undergoes a dramatic switch in
alternative splicing from CoAA to CoAM (Figure 7).
The P0 ( 5000 to þ88) minigene, though at a reduced
expression level, undergoes a similar switch, which has
similar timing to that of the endogenous CoAA gene at
stage EB4. In contrast, the P2 ( 1320 to þ88) and the P4
( 410 to þ88) minigenes containing the basal promoter
region have relatively high levels of expression of both
CoAA and CoAM but are unable to induce a complete
switch after RA induction (Figure 7). There was
up-regulation of CoAM, but the down-regulation of
CoAA was totally absent. Thus, when compared to the
endogenous gene or P0 minigene, the expression of CoAM
transcript from the P2 and P4 minigene fails to remain
dominant at the EB4 stage. In addition, the CMV-driven
minigene, in which the CoAA basal promoter was
substituted with a CMV promoter, shows an incomplete
switch in expression between CoAA and CoAM upon RA
induction. Quantiﬁcation of the PCR products in the gel is
shown in the lower panels of Figure 7. The transcriptional
level appears to be linked with alternative splicing on
the CoAA minigene. The higher transcriptional rates in
the P2 or P4 minigene are correlated with inadequate
CoAM splicing (Figures 5E and 7), whereas a lower
transcriptional rate in the P0 minigene shows an almost
complete switch from CoAA transcript to CoAM
transcript. These data imply a linked transcription rate
and alternative splicing regulation, and again suggests that
regulatory sequence and promoter context are involved
in regulating alternative splicing decisions. As switched
expression of CoAA and CoAM is correlated with EB
cavitation during stem cell diﬀerentiation, the CoAA gene
at this stage might be regulated at the alternative splicing
level through its promoter and cis-regulating sequence.
DISCUSSION
Increasing evidence indicates that alternative splicing
plays an important role in diﬀerentiation and develop-
ment. We show here, during neuronal stem cell diﬀer-
entiation, the alternative splicing of CoAA switches to its
dominant negative CoAM during the cavitation of the EB.
To our knowledge, this study is the ﬁrst to describe the
switched expression of alternative splicing variants with
antagonizing functions during EB cavitation. The switch
subsequently induces the expression of diﬀerentiation
marker Sox6. In addition, we show that the cis-regulating
element of the CoAA gene is required for the switch,
which leads to suppressed CoAA activity through both
reduced CoAA expression and functional inhibition by
CoAM. As shown in the proposed model (Figure 8), while
the basal promoter region activates transcription and
stimulates the production of CoAA, the cis-regulating
sequence represses transcription and stimulates alternative
splicing of CoAM. This balance is shifted, presumably
by regulating factors, binding the cis-regulating sequence
during EB cavitation. In human cancers, in which the
cis-regulating sequence was lost from the ampliﬁed CoAA
gene, this balance might be irreversibly altered so that
CoAA is overexpressed, consistent with our previous
observation (21); and CoAM may be underexpressed in
stem cells with disturbed normal diﬀerentiation. Sustained
coactivator CoAA expression would be predicted to impact
target genes with respect to both transcription and
alternative splicing, perhaps contributing to maintaining
an undiﬀerentiated cell phenotype.
The mRNA expression pattern of the endogenous
CoAA gene is complex. All three isoforms are identiﬁed
by RT-PCR in the majority of human tissues and are
conﬁrmed by subsequent nucleotide sequencing. Their
relative ratio and abundance in each tissue partially reﬂect
the alternative splicing regulation of the CoAA gene.
Because of the absence of additional upstream open
reading frame in the CoAA gene, the ratio change is less
likely due to the nonsense-mediated decay of mRNA (44).
Our analysis of protein levels is limited by the overlapping
nature of the primary sequences, and the generally low
levels of CoAM and CoAR. The endogenous CoAM
protein is diﬃcult to detect except in EB. CoAA, however,
is found in all cell lines analyzed, including P19 cells,
and is abundant in many tissues analyzed with immuno-
histochemistry. Although CoAR is a functional repressor
for CoAA, CoAR may not contribute signiﬁcantly to the
suppressed CoAA activity in the EB cavity, largely
because the low levels of expression and the absence of
up-regulation at EB stage (Figure 2A). This is probably
because both CoAA and CoAR share splicing junctions
Nucleic Acids Research, 2007, Vol. 35, No. 6 1929at exon 1 and exon 3. In contrast, CoAM utilizes a unique
splicing junction at exon 2, whose regulation may
be separated from that of CoAA. Thus, the observed
protein increase in EB cavity is contributed by CoAM.
In addition, CoAA protein is expressed in most cells at
the mouse E12.5 stage (Supplementary Figure S1). At
later stages of development, the expression appears to
become gradually restricted to cells undergoing further
diﬀerentiation (21). In adult mouse, CoAA expression is
also quite abundant in some tissues examined, including in
germ cells of testis (Supplementary Figure S2). The CoAA
expression pattern suggests a functional role of CoAA in
multiple tissues. Its dominant negatives, whose levels in
speciﬁc cells remain to be determined, may regulate CoAA
by changing their relative ratios through alternative
splicing.
The basal promoter of the CoAA gene appears to be
highly conserved among human, mouse and rat species
(Supplementary Figure S5). The cis-regulating sequence
is also quite conserved with a similar high density of
Alu repeats in human and B1 repeats in mouse. These
sequence features suggest that the CoAA gene may share
a similar regulation cross species. Although protein
factors associated with the CoAA regulatory sequences
are largely unknown, there are three conserved NF-Y sites
and one conserved Sp1 site located within the CoAA basal
promoter. In contrast, the CMV promoter contains four
cyclic AMP-responsive elements (CREs), three NF-kB
sites and one Sp1 site. The CMV promoter does not show
apparent homology with the CoAA promoter. However,
their distinct but overlapping protein-binding proﬁles
might provide the explanation that both p54
nrb and PSF
induce CoAM expression through the protein interactions
on the CoAA promoter, while only p54
nrb but not PSF
induces CoAM expression through the CMV promoter
(Figure 6A). Presumably, the protein complexes on each
promoter have diﬀerential interactions with p54
nrb and
PSF. Our ChIP analysis indeed suggests that there are
dynamic protein interactions between transcription/
splicing complexes and CoAA promoter sequence, or
Alu-rich cis-regulating sequence during diﬀerentiation
(Figure 6). Especially, the protein complexes increase the
interaction with the cis-regulating sequence at early stage
of EB formation (EB2). Thus, it is evident that the CoAA
gene may be regulated through its cis-regulating sequences
during EB formation. The functions of Alu repeats have
been shown to be associated with gene regulation
including CpG methylation-mediated gene silencing
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Figure 7. Switched alternative splicing of CoAA and CoAM is regulated by the upstream cis-regulating sequence. P19 cells were induced by 500nM
retinoic acid for 4 days. The cells were transfected with P0-, P2-, P4-, or CMV-minigene at each stage and the minigene transcripts were analyzed by
RT-PCR using isoform-speciﬁc primers. GAPDH served as a control. Endogenous CoAA and CoAM transcripts from native CoAA gene were
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Figure 8. Tentative model of CoAA alternative splicing regulation in
the embryoid body of stem cells. CoAA is produced by alternative
splicing with inclusion of the second exon. A competitive 50 alternative
splicing event excluding a portion of the second exon (2b) produces a
dominant negative variant, CoAM, which lacks the activation domain.
The basal promoter of the CoAA gene, shown as an open box,
promotes splicing of the CoAA form, which is expressed in the outer
layer of the embryoid body (gray). The upstream cis-regulating
sequence, shown as a ﬁlled box, promotes alternative splicing of
CoAM, which is expressed in the cavity of EB (white). The loss of
upstream cis-regulating element in cancer may prevent the alternative
splicing switch and disrupt stem cell diﬀerentiation.
1930 Nucleic Acids Research, 2007, Vol. 35, No. 6(45–47), and hormone-induced gene activation (48).
Evidence has also suggested that Alu repeats contain
alternative splicing enhancers and silencers, and partici-
pate in alternative splicing regulation (49). In addition,
the repetitive nature of Alu repeats may facilitate DNA
rearrangement, which explains the aberration of the
CoAA gene in human cancers (50,21). Although the
precise size of the CoAA cis-regulating element has not
been deﬁned, our results suggest that the Alu-rich region
critically regulates CoAA expression and alternative
splicing, at least during stem cell diﬀerentiation.
Since both the RRMs and the C-terminal activation
domain are required for CoAA activity (16), the
alternatively spliced CoAM may compete with CoAA
through their shared RRMs. The RRM domains have
been shown to be the most abundant protein domains
in nuclear proteins (51,52), however, several available
crystal structure analyses indicate the structures of
RRMs are highly speciﬁc. For example, the RRMs of
hnRNP A1, U1A and sex lethal have their unique peptide
architectures with speciﬁc interacting surfaces
toward nucleic acids or proteins (53). In this regard, the
RRM-containing CoAM may compete only with CoAA
for the same binding partners and thus serve as a CoAA
dominant negative. The abundance of CoAM will
then become critical for controlling endogenous CoAA
function. And therefore, the switched alternative splicing
between CoAA and CoAM may be an important
approach to ﬁne-tune CoAA activity, especially during
diﬀerentiation at the EB stage.
Cell fate determination in stem cell diﬀerentiation
involves a complex pattern of gene regulation including
alternative splicing (54,55). Although RA is a nuclear
receptor ligand, its target genes during diﬀerentiation
are largely undetermined. CoAA as a nuclear receptor
coactivator may also regulate an array of genes, including
their alternative splicing. A cascade of alternative splicing
regulation during diﬀerentiation and development has
been documented, which might facilitate the understand-
ing of the CoAA function. One of the best examples is the
sex-lethal (Sxl) gene in sex determination in Drosophila.
Sxl regulates transformer, which in turn regulates double-
sex, all through alternative splicing (6). The Sxl transcript
is alternatively spliced producing an RRM-containing
protein that stimulates its own splicing via a positive
feedback mechanism. This establishes and maintains
the status of Sxl alternative splicing and determines
phenotype of male or female in cells (56). Similarly, the
CoAA gene is also alternatively spliced producing splicing
regulators with antagonized functions. In addition, CoAA
regulates its own gene through positive feedback mechan-
ism (21). In the absence of RA induction, overexpression
of CoAM alone, which shares identical RRMs with
CoAA, can signiﬁcantly stimulate the production of the
diﬀerentiation marker Sox6 (Figure 4). Interestingly, Sox6
and some Sox family members have also been shown to
regulate alternative splicing (37). Thus, a potential cascade
of splicing regulation involving CoAA might exist during
stem cell diﬀerentiation. Further studies are needed to
conﬁrm if the on/oﬀ switch of CoAA controls speciﬁc
diﬀerentiation programs in the mammalian system and
which factors, including PSF and p54
nrb, are responsible
for the switch.
In summary, we ﬁnd that the alternative splicing of
CoAA switches to its dominant negative form
CoAM during EB cavitation of EC cell diﬀerentiation.
In addition, we show that CoAA promoter and cis-
regulating sequences play an important role in regulating
alternative splicing. The ﬁnding not only provides a
potential explanation for oncogenic CoAA in regulating
stem cell diﬀerentiation, but also supports the concept that
the promoter/enhancer participates in alternative splicing
decisions.
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Supplementary Data is available at NAR Online.
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